@Slogger@Gorillas95 your posts in this thread are a lot more realistic than the vast majority on HC. But frankly, for mine, you're still way too optimistic. $20m addressable market and 4 generics already there, how the hell is ACR's meant get any real traction??? Not to mention the cost that would be involved in doing so. It's no wonder few companies focus on creating topical generics, the markets are hilariously tiny.
Add to My Watchlist
What is My Watchlist?
